Search
for

    Sort by

    Research 30 of 1000+

    1. BPH: epidemiology and comorbidities. PubMed · 2006 · 386 citations
    2. Urinary Retention in Patients with BPH Treated with Finasteride or Placebo over 4 Years European Urology · 2000 · 109 citations
    3. Combined Sabal and Urtica extract vs finasteride in BPH (Alken stage I–II) Der Urologe · 1997 · 69 citations
    4. Reduced levels of 5-α reductase 2 in adult prostate tissue and implications for BPH therapy 2011 · 39 citations
    5. BPH: costs and treatment outcomes. PubMed · 2006 · 34 citations
    6. Current Pharmacological Treatment for Male LUTS due to BPH: Dutasteride or Finasteride? Current Drug Targets · 2015 · 21 citations
    7. Fixed-dose combination PRO 160/120 of sabal and urtica extracts improves nocturia in men with LUTS suggestive of BPH: re-evaluation of four controlled clinical studies World Journal of Urology · 2014 · 14 citations
    8. The prevention of benign prostatic hyperplasia (bph) Medical Hypotheses · 2016 · 12 citations
    9. Economic Issues in the Treatment of BPH European Urology Supplements · 2006 · 11 citations
    10. Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study Journal of Clinical Medicine · 2022 · 6 citations
    11. Administration of Caesalpinia bonduc Seed Extracts Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia (BPH) in Male Wistar Rats Research and reports in urology · 2022 · 6 citations
    12. Non-surgical management of BPH: An updated review of current literature and state of the art on natural compounds and medical therapy Archivio Italiano di Urologia e Andrologia · 2024 · 5 citations
    13. Medikamentöse Therapie der BPH Ist eine Kombinationstherapie mit 5α-Reduktasehemmern und α-Rezeptorenblockern sinnvoll? Der Urologe · 2002 · 4 citations
    14. WS PRO 160 I 120 mg (a combination of sabal and urtica extract) in patients with LUTS related to BPH Therapeutic advances in urology · 2019 · 3 citations
    15. Scientific Evaluation of A Unani Pharmacopoeia-Based Formulation on BPH in Animal Model International Journal of Preventive Medicine and Health (IJPMH) · 2023 · 2 citations
    16. Medical Therapies for Treatment of BPH: Special Considerations in Elderly Men Current Geriatrics Reports · 2019 · 2 citations
    17. The effect of 5-α reductase inhibitor on Th1, Th2, and Th17 cell-related inflammatory response in BPH World Journal of Urology · 2023 · 1 citations
    18. Effect of a Benign Prostatic Hyperplasia (BPH) Xenobiotic - Croton membranaceus Müll.Arg. Root Extract on CYP1A2, CYP3A4, CYP2D6, and GSTM1 Drug Metabolizing Enzymes in Rat Model 2020 · 1 citations
    19. PD19-08 MARIJUANA, ALCOHOL, ED AND DEPRESSION: EPIDEMIOLOGIC CORRELATIONS WITH BPH/LUTS 2019 · 1 citations
    20. Effect of ethanol extract of Zapoteca portoricensis stem on liver, kidney and prostatic biomarkers of testosterone-induced benign prostate hyperplasia (BPH) in male albino rats AUSTRALIAN JOURNAL OF BASIC AND APPLIED SCIENCES · 2018 · 1 citations
    21. Re: Can Long-Term LUTS/BPH Pharmacological Treatment Alter the Outcomes of Surgical Intervention? The Journal of Urology · 2017 · 1 citations
    22. Study on the mechanism that SNPs related to sex hormone metabolism regulate the imbalance of sex hormones and lead to BPHin rats Figshare · 2026
    23. Study on the mechanism that SNPs related to sex hormone metabolism regulate the imbalance of sex hormones and lead to BPHin rats Figshare · 2026
    24. Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS) Figshare · 2026
    25. Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS) Figshare · 2026
    26. Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS) The Aging Male · 2026
    27. Modulation of AR-FGF-2-TGF beta Axis by Cosmos caudatus Suppresses Prostatic Epithelial Proliferation in a BPH Rat Model: A Comparative Study with Finasteride Journal of Multidisciplinary Applied Natural Science · 2026
    28. Study on the mechanism that SNPs related to sex hormone metabolism regulate the imbalance of sex hormones and lead to BPH in rats 2025
    29. The endoscopic surgical monitoring system-guided impact factors exploring of blood loss and fluid absorption during plasmakinetic TURP: a prospective study in high-risk BPH patients BMC Urology · 2025
    30. Impact of Finasteride on Serum PSA Levels in Men With BPH: A Systematic Review International Journal of Social health · 2025